drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00448 | DB01259 | 1,215 | 392 | [
"DDInter1022",
"DDInter1024"
] | Lansoprazole | Lapatinib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1215,
24,
392
]
],
[
[
1215,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1215,
18,
4602
],
[
4602,
57,
392
]
],
[
[
1215,
21,
28674
],
[
28674... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Lansoprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Lansoprazole (Compound) downregulates SUPV3L1 (Gene) and SUPV3L1 (Gene) is downregulated by Lapatinib (Compound)
Lansoprazole (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Lapatinib ... |
DB00366 | DB00408 | 1,594 | 1,408 | [
"DDInter600",
"DDInter1099"
] | Doxylamine | Loxapine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | An antipsychotic agent used in schizophrenia. [PubChem] | Moderate | 1 | [
[
[
1594,
24,
1408
]
],
[
[
1594,
63,
902
],
[
902,
40,
1408
]
],
[
[
1594,
24,
1119
],
[
1119,
1,
1408
]
],
[
[
1594,
24,
523
],
[
523,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loxapine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Loxapine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Loxapine (Compou... |
DB00598 | DB00938 | 1,523 | 455 | [
"DDInter1013",
"DDInter1635"
] | Labetalol | Salmeterol | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Major | 2 | [
[
[
1523,
25,
455
]
],
[
[
1523,
25,
688
],
[
688,
63,
455
]
],
[
[
1523,
40,
371
],
[
371,
63,
455
]
],
[
[
1523,
40,
1188
],
[
1188,
... | [
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
],
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may... | Labetalol may lead to a major life threatening interaction when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Labetalol (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate dis... |
DB00734 | DB11986 | 1,664 | 484 | [
"DDInter1605",
"DDInter648"
] | Risperidone | Entrectinib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1664,
24,
484
]
],
[
[
1664,
23,
112
],
[
112,
23,
484
]
],
[
[
1664,
24,
222
],
[
222,
23,
484
]
],
[
[
1664,
24,
774
],
[
774,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and ... |
DB09276 | DB11989 | 381 | 1,434 | [
"DDInter1682",
"DDInter183"
] | Sodium aurothiomalate | Benznidazole | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no valu... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
381,
24,
1434
]
],
[
[
381,
63,
375
],
[
375,
24,
1434
]
],
[
[
381,
24,
148
],
[
148,
63,
1434
]
],
[
[
381,
24,
1480
],
[
1480,
... | [
[
[
"Sodium aurothiomalate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Sodium aurothiomalate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cer... | Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseas... |
DB08882 | DB12141 | 1,281 | 971 | [
"DDInter1070",
"DDInter817"
] | Linagliptin | Gilteritinib | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1281,
24,
971
]
],
[
[
1281,
63,
485
],
[
485,
24,
971
]
],
[
[
1281,
24,
1097
],
[
1097,
24,
971
]
],
[
[
1281,
24,
1598
],
[
1598,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and ... |
DB00802 | DB01233 | 1,322 | 1,311 | [
"DDInter43",
"DDInter1197"
] | Alfentanil | Metoclopramide | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1322,
24,
1311
]
],
[
[
1322,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1322,
24,
1383
],
[
1383,
63,
1311
]
],
[
[
1322,
24,
629
],
[
6... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Alfentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) i... | Alfentanil (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when take... |
DB00413 | DB06282 | 1,346 | 516 | [
"DDInter1505",
"DDInter1053"
] | Pramipexole | Levocetirizine | Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the mos... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1346,
24,
516
]
],
[
[
1346,
63,
701
],
[
701,
24,
516
]
],
[
[
1346,
24,
1614
],
[
1614,
24,
516
]
],
[
[
1346,
24,
407
],
[
407,
... | [
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Na... |
DB00031 | DB06081 | 20 | 1,046 | [
"DDInter1764",
"DDInter286"
] | Tenecteplase | Caplacizumab | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
20,
25,
1046
]
],
[
[
20,
23,
1631
],
[
1631,
62,
1046
]
],
[
[
20,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
20,
24,
1427
],
[
1427,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric... | Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dex... |
DB06788 | DB13139 | 1,616 | 1,032 | [
"DDInter864",
"DDInter1063"
] | Histrelin | Levosalbutamol | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1616,
24,
1032
]
],
[
[
1616,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1616,
24,
124
],
[
124,
24,
1032
]
],
[
[
1616,
63,
594
],
[
594,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Caboza... | Histrelin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may ca... |
DB00619 | DB10429 | 1,419 | 200 | [
"DDInter909",
"DDInter282"
] | Imatinib | Candida albicans | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1419,
24,
200
]
],
[
[
1419,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1419,
25,
976
],
[
976,
24,
200
]
],
[
[
1419,
25,
1019
],
[
1019,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Imatinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may ... |
DB00968 | DB11921 | 1,551 | 1,019 | [
"DDInter1185",
"DDInter492"
] | Methyldopa | Deflazacort | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1551,
24,
1019
]
],
[
[
1551,
23,
959
],
[
959,
24,
1019
]
],
[
[
1551,
24,
1344
],
[
1344,
24,
1019
]
],
[
[
1551,
62,
245
],
[
245,
... | [
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Methyldopa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glipizide"
],
[
... | Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagl... |
DB00270 | DB01285 | 1,428 | 708 | [
"DDInter993",
"DDInter445"
] | Isradipine | Corticotropin | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1428,
24,
708
]
],
[
[
1428,
24,
1450
],
[
1450,
63,
708
]
],
[
[
1428,
63,
1184
],
[
1184,
24,
708
]
],
[
[
1428,
24,
544
],
[
544,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and... |
DB00682 | DB13873 | 126 | 1,534 | [
"DDInter1951",
"DDInter719"
] | Warfarin | Fenofibric acid | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Major | 2 | [
[
[
126,
25,
1534
]
],
[
[
126,
24,
780
],
[
780,
24,
1534
]
],
[
[
126,
63,
305
],
[
305,
24,
1534
]
],
[
[
126,
62,
663
],
[
663,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid and Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Warfarin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01110 | DB06207 | 86 | 910 | [
"DDInter1209",
"DDInter1667"
] | Miconazole | Silodosin | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Moderate | 1 | [
[
[
86,
24,
910
]
],
[
[
86,
6,
8374
],
[
8374,
45,
910
]
],
[
[
86,
21,
28779
],
[
28779,
60,
910
]
],
[
[
86,
24,
484
],
[
484,
63... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Miconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Silodosin (Compound)
Miconazole (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Silodosin (Compound)
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entre... |
DB00554 | DB00619 | 1,027 | 1,419 | [
"DDInter1478",
"DDInter909"
] | Piroxicam | Imatinib | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
1027,
24,
1419
]
],
[
[
1027,
6,
6017
],
[
6017,
45,
1419
]
],
[
[
1027,
24,
222
],
[
222,
62,
1419
]
],
[
[
1027,
24,
1619
],
[
1619,... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Piroxicam",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Piroxicam (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Imatinib (Compound)
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Imatinib
Piroxicam may cause a mo... |
DB01175 | DB09564 | 318 | 1,296 | [
"DDInter672",
"DDInter930"
] | Escitalopram | Insulin degludec | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
318,
24,
1296
]
],
[
[
318,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
318,
24,
659
],
[
659,
24,
1296
]
],
[
[
318,
25,
1151
],
[
1151,
... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Vilantero... |
DB01206 | DB08908 | 37 | 713 | [
"DDInter1086",
"DDInter564"
] | Lomustine | Dimethyl fumarate | An alkylating agent of value against both hematologic malignancies and solid tumors. | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
37,
24,
713
]
],
[
[
37,
24,
996
],
[
996,
24,
713
]
],
[
[
37,
63,
60
],
[
60,
24,
713
]
],
[
[
37,
74,
552
],
[
552,
24,
... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
],
... | Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine a... |
DB00460 | DB04571 | 612 | 226 | [
"DDInter1929",
"DDInter1877"
] | Verteporfin | Trioxsalen | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative obtained from several plants, mainly Psoralea corylifolia. Like other psoralens it causes photosensitization of the skin. It is administered either topically or orally in conjunction with UV-A (the least damaging for... | Moderate | 1 | [
[
[
612,
24,
226
]
],
[
[
612,
24,
92
],
[
92,
24,
226
]
],
[
[
612,
24,
1040
],
[
1040,
7,
13128
],
[
13128,
46,
226
]
],
[
[
612,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trioxsalen"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
],
[... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trioxsalen
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Da... |
DB00741 | DB01122 | 167 | 158 | [
"DDInter885",
"DDInter61"
] | Hydrocortisone | Ambenonium | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis. | Moderate | 1 | [
[
[
167,
24,
158
]
],
[
[
167,
40,
870
],
[
870,
24,
158
]
],
[
[
167,
1,
251
],
[
251,
24,
158
]
],
[
[
167,
25,
1011
],
[
1011,
63... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ambenonium"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} m... | Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium
Hydrocortisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases whe... |
DB00086 | DB00682 | 1,167 | 126 | [
"DDInter1712",
"DDInter1951"
] | Streptokinase | Warfarin | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
1167,
25,
126
]
],
[
[
1167,
23,
944
],
[
944,
62,
126
]
],
[
[
1167,
24,
477
],
[
477,
62,
126
]
],
[
[
1167,
24,
557
],
[
557,
... | [
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile... | Streptokinase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Warfarin
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostaz... |
DB00502 | DB01181 | 1,300 | 1,532 | [
"DDInter853",
"DDInter906"
] | Haloperidol | Ifosfamide | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1300,
24,
1532
]
],
[
[
1300,
6,
7524
],
[
7524,
45,
1532
]
],
[
[
1300,
21,
29209
],
[
29209,
60,
1532
]
],
[
[
1300,
63,
1648
],
[
1... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)... | Haloperidol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound)
Haloperidol (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Al... |
DB00757 | DB14568 | 1,166 | 982 | [
"DDInter581",
"DDInter1000"
] | Dolasetron | Ivosidenib | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1166,
25,
982
]
],
[
[
1166,
23,
112
],
[
112,
23,
982
]
],
[
[
1166,
64,
1081
],
[
1081,
24,
982
]
],
[
[
1166,
24,
543
],
[
543,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Dolasetron may lead to a major life threatening interaction when taken with Nicardipine and Nicardipine may ca... |
DB01124 | DB14730 | 1,411 | 1,412 | [
"DDInter1828",
"DDInter264"
] | Tolbutamide | Calaspargase pegol | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1411,
24,
1412
]
],
[
[
1411,
62,
1347
],
[
1347,
24,
1412
]
],
[
[
1411,
24,
5
],
[
5,
24,
1412
]
],
[
[
1411,
63,
1144
],
[
1144,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],... | Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide... |
DB00063 | DB04865 | 366 | 4 | [
"DDInter659",
"DDInter1335"
] | Eptifibatide | Omacetaxine mepesuccinate | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
366,
25,
4
]
],
[
[
366,
24,
738
],
[
738,
63,
4
]
],
[
[
366,
25,
39
],
[
39,
63,
4
]
],
[
[
366,
25,
1213
],
[
1213,
24,
... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Eptifibatide may lead to a major life threatening interaction when taken with Panobinostat and Pa... |
DB00586 | DB01276 | 1,512 | 123 | [
"DDInter537",
"DDInter706"
] | Diclofenac | Exenatide | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1512,
24,
123
]
],
[
[
1512,
63,
1252
],
[
1252,
23,
123
]
],
[
[
1512,
24,
1573
],
[
1573,
24,
123
]
],
[
[
1512,
63,
217
],
[
217,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may ... |
DB01056 | DB04865 | 571 | 4 | [
"DDInter1823",
"DDInter1335"
] | Tocainide | Omacetaxine mepesuccinate | An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
571,
24,
4
]
],
[
[
571,
18,
8397
],
[
8397,
46,
4
]
],
[
[
571,
24,
1683
],
[
1683,
63,
4
]
],
[
[
571,
63,
599
],
[
599,
24,
... | [
[
[
"Tocainide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Tocainide",
"{u} (Compound) downregulates {v} (Gene)",
"PPP2R3C"
],
[
"PPP2R3C",
"{u} (Gene) is up... | Tocainide (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB06176 | DB09054 | 1,342 | 384 | [
"DDInter1616",
"DDInter905"
] | Romidepsin | Idelalisib | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1342,
24,
384
]
],
[
[
1342,
64,
318
],
[
318,
23,
384
]
],
[
[
1342,
63,
479
],
[
479,
23,
384
]
],
[
[
1342,
25,
1618
],
[
1618,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalo... | Romidepsin may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause ... |
DB00196 | DB01267 | 600 | 519 | [
"DDInter743",
"DDInter1381"
] | Fluconazole | Paliperidone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
600,
24,
519
]
],
[
[
600,
24,
1664
],
[
1664,
1,
519
]
],
[
[
600,
25,
924
],
[
924,
1,
519
]
],
[
[
600,
6,
7524
],
[
7524,
45... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Fluco... |
DB11689 | DB12130 | 321 | 1,017 | [
"DDInter1659",
"DDInter1094"
] | Selumetinib | Lorlatinib | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
321,
25,
1017
]
],
[
[
321,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
321,
24,
1421
],
[
1421,
63,
1017
]
],
[
[
321,
63,
126
],
[
126,
... | [
[
[
"Selumetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrix... |
DB01105 | DB14509 | 222 | 1,399 | [
"DDInter1665",
"DDInter1081"
] | Sibutramine | Lithium carbonate | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Major | 2 | [
[
[
222,
25,
1399
]
],
[
[
222,
63,
874
],
[
874,
23,
1399
]
],
[
[
222,
24,
1574
],
[
1574,
23,
1399
]
],
[
[
222,
24,
1385
],
[
1385,
... | [
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Urea and Ure... |
DB00738 | DB11113 | 485 | 657 | [
"DDInter1420",
"DDInter307"
] | Pentamidine | Castor oil | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
485,
24,
657
]
],
[
[
485,
24,
1079
],
[
1079,
24,
657
]
],
[
[
485,
24,
927
],
[
927,
63,
657
]
],
[
[
485,
25,
540
],
[
540,
2... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Enc... |
DB00781 | DB14761 | 1,481 | 242 | [
"DDInter1489",
"DDInter1578"
] | Polymyxin B | Remdesivir | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1481,
24,
242
]
],
[
[
1481,
25,
361
],
[
361,
24,
242
]
],
[
[
1481,
63,
1555
],
[
1555,
24,
242
]
],
[
[
1481,
24,
50
],
[
50,
... | [
[
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
],
[
"Neomycin",... | Polymyxin B may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause ... |
DB01324 | DB08882 | 178 | 1,281 | [
"DDInter1490",
"DDInter1070"
] | Polythiazide | Linagliptin | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
178,
24,
1281
]
],
[
[
178,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
178,
21,
28762
],
[
28762,
60,
1281
]
],
[
[
178,
63,
251
],
[
251,
... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Polythiazide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Linagliptin (Compound)
Polythiazide may cause a moderate intera... |
DB00734 | DB13928 | 1,664 | 1,385 | [
"DDInter1605",
"DDInter1660"
] | Risperidone | Semaglutide | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1664,
24,
1385
]
],
[
[
1664,
25,
1154
],
[
1154,
24,
1385
]
],
[
[
1664,
63,
1144
],
[
1144,
24,
1385
]
],
[
[
1664,
24,
1148
],
[
11... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasire... | Risperidone may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may... |
DB01087 | DB01166 | 1,520 | 477 | [
"DDInter1520",
"DDInter379"
] | Primaquine | Cilostazol | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1520,
24,
477
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1520,
21,
28658
],
[
28658,
60,
477
]
],
[
[
1520,
62,
112
],
[
112,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Primaquine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cilostazol (Compound)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metro... |
DB00241 | DB01259 | 288 | 392 | [
"DDInter257",
"DDInter1024"
] | Butalbital | Lapatinib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
288,
24,
392
]
],
[
[
288,
24,
1135
],
[
1135,
62,
392
]
],
[
[
288,
24,
112
],
[
112,
23,
392
]
],
[
[
288,
24,
466
],
[
466,
6... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronid... |
DB06448 | DB09073 | 171 | 951 | [
"DDInter1087",
"DDInter1379"
] | Lonafarnib | Palbociclib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Major | 2 | [
[
[
171,
25,
951
]
],
[
[
171,
25,
1476
],
[
1476,
63,
951
]
],
[
[
171,
64,
467
],
[
467,
24,
951
]
],
[
[
171,
25,
578
],
[
578,
2... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} ... | Lonafarnib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lonafarnib may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate i... |
DB01261 | DB01583 | 170 | 624 | [
"DDInter1679",
"DDInter1075"
] | Sitagliptin | Liotrix | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
170,
24,
624
]
],
[
[
170,
63,
1152
],
[
1152,
1,
624
]
],
[
[
170,
63,
542
],
[
542,
40,
624
]
],
[
[
170,
6,
3486
],
[
3486,
4... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Comp... |
DB01241 | DB11979 | 1,206 | 1,320 | [
"DDInter812",
"DDInter625"
] | Gemfibrozil | Elagolix | Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA appr... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
1206,
25,
1320
]
],
[
[
1206,
24,
129
],
[
129,
24,
1320
]
],
[
[
1206,
63,
663
],
[
663,
24,
1320
]
],
[
[
1206,
24,
1017
],
[
1017,
... | [
[
[
"Gemfibrozil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Gemfibrozil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzaluta... | Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and ... |
DB00862 | DB12500 | 1,005 | 283 | [
"DDInter1918",
"DDInter714"
] | Vardenafil | Fedratinib | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1005,
24,
283
]
],
[
[
1005,
25,
351
],
[
351,
23,
283
]
],
[
[
1005,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1005,
24,
951
],
[
951,
... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib... | Vardenafil may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a mode... |
DB00341 | DB09061 | 1,242 | 1,627 | [
"DDInter343",
"DDInter284"
] | Cetirizine | Cannabidiol | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
1242,
24,
1627
]
],
[
[
1242,
24,
1594
],
[
1594,
24,
1627
]
],
[
[
1242,
63,
1648
],
[
1648,
24,
1627
]
],
[
[
1242,
24,
407
],
[
407... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Alde... |
DB00519 | DB00635 | 1,638 | 1,573 | [
"DDInter1843",
"DDInter1515"
] | Trandolapril | Prednisone | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1638,
24,
1573
]
],
[
[
1638,
24,
175
],
[
175,
40,
1573
]
],
[
[
1638,
63,
251
],
[
251,
1,
1573
]
],
[
[
1638,
24,
167
],
[
167,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Predni... |
DB08816 | DB11560 | 578 | 1,678 | [
"DDInter1802",
"DDInter1038"
] | Ticagrelor | Lesinurad | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Moderate | 1 | [
[
[
578,
24,
1678
]
],
[
[
578,
63,
263
],
[
263,
24,
1678
]
],
[
[
578,
25,
913
],
[
913,
63,
1678
]
],
[
[
578,
24,
1040
],
[
1040,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
],
[
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Ticagrelor may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a m... |
DB01240 | DB14357 | 885 | 944 | [
"DDInter657",
"DDInter347"
] | Epoprostenol | Chamomile | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
885,
23,
944
]
],
[
[
885,
24,
256
],
[
256,
23,
944
]
],
[
[
885,
63,
582
],
[
582,
23,
944
]
],
[
[
885,
25,
792
],
[
792,
23,... | [
[
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
... | Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplas... |
DB00675 | DB01591 | 888 | 667 | [
"DDInter1744",
"DDInter1696"
] | Tamoxifen | Solifenacin | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
888,
24,
667
]
],
[
[
888,
6,
8374
],
[
8374,
45,
667
]
],
[
[
888,
21,
29462
],
[
29462,
60,
667
]
],
[
[
888,
23,
112
],
[
112,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Tamoxifen (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Solifenacin (Compound)
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metr... |
DB00218 | DB00570 | 1,176 | 147 | [
"DDInter1247",
"DDInter1936"
] | Moxifloxacin | Vinblastine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Minor | 0 | [
[
[
1176,
23,
147
]
],
[
[
1176,
23,
134
],
[
134,
24,
147
]
],
[
[
1176,
6,
3199
],
[
3199,
57,
147
]
],
[
[
1176,
21,
29196
],
[
29196,
... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinorelbine"
],
[
... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Moxifloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Vinblastine (Compound)
Moxifl... |
DB01065 | DB12130 | 43 | 1,017 | [
"DDInter1142",
"DDInter1094"
] | Melatonin | Lorlatinib | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice g... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
43,
24,
1017
]
],
[
[
43,
63,
126
],
[
126,
24,
1017
]
],
[
[
43,
24,
1033
],
[
1033,
24,
1017
]
],
[
[
43,
62,
752
],
[
752,
24... | [
[
[
"Melatonin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Melatonin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Melatonin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Melatonin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may... |
DB11003 | DB11817 | 748 | 1,259 | [
"DDInter100",
"DDInter165"
] | Anthrax vaccine | Baricitinib | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
748,
24,
1259
]
],
[
[
748,
63,
384
],
[
384,
25,
1259
]
],
[
[
748,
24,
1619
],
[
1619,
64,
1259
]
],
[
[
748,
24,
351
],
[
351,
... | [
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
... | Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib m... |
DB00176 | DB09074 | 529 | 1,362 | [
"DDInter770",
"DDInter1327"
] | Fluvoxamine | Olaparib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
529,
24,
1362
]
],
[
[
529,
24,
896
],
[
896,
24,
1362
]
],
[
[
529,
25,
2
],
[
2,
24,
1362
]
],
[
[
529,
24,
214
],
[
214,
63,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Fluvoxamine may lead to a major life threatening interaction when taken with Alosetron and Alosetron may cause a mo... |
DB00280 | DB00731 | 494 | 1,144 | [
"DDInter575",
"DDInter1269"
] | Disopyramide | Nateglinide | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
494,
24,
1144
]
],
[
[
494,
6,
6943
],
[
6943,
45,
1144
]
],
[
[
494,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
494,
24,
629
],
[
629,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"ORM1"
],
[
"ORM1",
"{u} (Gene) is bound by {v} (Compound)"... | Disopyramide (Compound) binds ORM1 (Gene) and ORM1 (Gene) is bound by Nateglinide (Compound)
Disopyramide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and... |
DB00486 | DB00557 | 1,614 | 252 | [
"DDInter1253",
"DDInter895"
] | Nabilone | Hydroxyzine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Moderate | 1 | [
[
[
1614,
24,
252
]
],
[
[
1614,
24,
851
],
[
851,
1,
252
]
],
[
[
1614,
24,
623
],
[
623,
40,
252
]
],
[
[
1614,
24,
537
],
[
537,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Hydroxyzine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Compound)
Na... |
DB01136 | DB01364 | 772 | 22 | [
"DDInter305",
"DDInter650"
] | Carvedilol | Ephedrine | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
772,
24,
22
]
],
[
[
772,
63,
1445
],
[
1445,
1,
22
]
],
[
[
772,
6,
3576
],
[
3576,
45,
22
]
],
[
[
772,
21,
28730
],
[
28730,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Carvedilol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Ephedrine (Compound)
Carvedilol (Compound) causes Psychotic disorder (Side Effect... |
DB00182 | DB01105 | 80 | 222 | [
"DDInter84",
"DDInter1665"
] | Amphetamine | Sibutramine | Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 ... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
80,
25,
222
]
],
[
[
80,
6,
6112
],
[
6112,
45,
222
]
],
[
[
80,
21,
28698
],
[
28698,
60,
222
]
],
[
[
80,
24,
1419
],
[
1419,
... | [
[
[
"Amphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Amphetamine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sibu... | Amphetamine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Sibutramine (Compound)
Amphetamine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Sibutramine (Compound)
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Ima... |
DB00877 | DB11827 | 629 | 433 | [
"DDInter1678",
"DDInter669"
] | Sirolimus | Ertugliflozin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
629,
24,
433
]
],
[
[
629,
24,
1654
],
[
1654,
63,
433
]
],
[
[
629,
24,
959
],
[
959,
24,
433
]
],
[
[
629,
63,
251
],
[
251,
2... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glip... |
DB11986 | DB13179 | 484 | 68 | [
"DDInter648",
"DDInter1882"
] | Entrectinib | Troleandomycin | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
484,
25,
68
]
],
[
[
484,
63,
1413
],
[
1413,
23,
68
]
],
[
[
484,
62,
222
],
[
222,
23,
68
]
],
[
[
484,
23,
466
],
[
466,
23,
... | [
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fexofenadine"
],
[
"Fe... | Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine and Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and... |
DB00195 | DB01064 | 726 | 1,148 | [
"DDInter198",
"DDInter987"
] | Betaxolol (ophthalmic) | Isoprenaline | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
726,
24,
1148
]
],
[
[
726,
24,
1636
],
[
1636,
24,
1148
]
],
[
[
726,
1,
887
],
[
887,
24,
1148
]
],
[
[
726,
6,
1704
],
[
1704,
... | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[... | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Be... |
DB00004 | DB00108 | 669 | 1,066 | [
"DDInter499",
"DDInter1268"
] | Denileukin diftitox | Natalizumab | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Major | 2 | [
[
[
669,
25,
1066
]
],
[
[
669,
24,
949
],
[
949,
63,
1066
]
],
[
[
669,
25,
375
],
[
375,
64,
1066
]
],
[
[
669,
24,
738
],
[
738,
... | [
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxo... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Natalizumab
De... |
DB00705 | DB01177 | 441 | 77 | [
"DDInter496",
"DDInter904"
] | Delavirdine | Idarubicin | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
441,
24,
77
]
],
[
[
441,
6,
6017
],
[
6017,
45,
77
]
],
[
[
441,
21,
28987
],
[
28987,
60,
77
]
],
[
[
441,
25,
543
],
[
543,
2... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)... | Delavirdine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Delavirdine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Idarubicin (Compound)
Delavirdine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a... |
DB00242 | DB01410 | 1,064 | 423 | [
"DDInter392",
"DDInter375"
] | Cladribine | Ciclesonide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Major | 2 | [
[
[
1064,
25,
423
]
],
[
[
1064,
25,
1573
],
[
1573,
1,
423
]
],
[
[
1064,
64,
1351
],
[
1351,
40,
423
]
],
[
[
1064,
25,
1486
],
[
1486,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ciclesonide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} ... | Cladribine may lead to a major life threatening interaction when taken with Prednisone and Prednisone (Compound) resembles Ciclesonide (Compound)
Cladribine may lead to a major life threatening interaction when taken with Flunisolide and Flunisolide (Compound) resembles Ciclesonide (Compound)
Cladribine may lead to a m... |
DB01105 | DB06448 | 222 | 171 | [
"DDInter1665",
"DDInter1087"
] | Sibutramine | Lonafarnib | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Minor | 0 | [
[
[
222,
23,
171
]
],
[
[
222,
63,
1347
],
[
1347,
24,
171
]
],
[
[
222,
24,
761
],
[
761,
24,
171
]
],
[
[
222,
24,
498
],
[
498,
6... | [
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lonafarnib"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and S... |
DB00060 | DB00586 | 912 | 1,512 | [
"DDInter947",
"DDInter537"
] | Interferon beta-1a | Diclofenac | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
912,
24,
1512
]
],
[
[
912,
24,
1263
],
[
1263,
63,
1512
]
],
[
[
912,
24,
1622
],
[
1622,
24,
1512
]
],
[
[
912,
63,
305
],
[
305,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Voricon... |
DB00575 | DB01114 | 1,020 | 272 | [
"DDInter412",
"DDInter362"
] | Clonidine | Chlorpheniramine | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1020,
24,
272
]
],
[
[
1020,
24,
849
],
[
849,
63,
272
]
],
[
[
1020,
63,
128
],
[
128,
24,
272
]
],
[
[
1020,
6,
12523
],
[
12523,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramin... |
DB00222 | DB01284 | 245 | 1,042 | [
"DDInter825",
"DDInter1782"
] | Glimepiride | Tetracosactide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
245,
24,
1042
]
],
[
[
245,
24,
455
],
[
455,
23,
1042
]
],
[
[
245,
24,
659
],
[
659,
62,
1042
]
],
[
[
245,
24,
461
],
[
461,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vi... |
DB00514 | DB01219 | 506 | 716 | [
"DDInter527",
"DDInter473"
] | Dextromethorphan | Dantrolene | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
506,
24,
716
]
],
[
[
506,
6,
8374
],
[
8374,
45,
716
]
],
[
[
506,
10,
11594
],
[
11594,
49,
716
]
],
[
[
506,
21,
28722
],
[
28722,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} ... | Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dantrolene (Compound)
Dextromethorphan (Compound) palliates multiple sclerosis (Disease) and multiple sclerosis (Disease) is palliated by Dantrolene (Compound)
Dextromethorphan (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) i... |
DB04855 | DB09065 | 540 | 760 | [
"DDInter602",
"DDInter424"
] | Dronedarone | Cobicistat | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
540,
25,
760
]
],
[
[
540,
63,
1101
],
[
1101,
23,
760
]
],
[
[
540,
25,
1374
],
[
1374,
23,
760
]
],
[
[
540,
63,
723
],
[
723,
... | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Dronedarone may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may caus... |
DB00593 | DB00673 | 1,464 | 723 | [
"DDInter695",
"DDInter112"
] | Ethosuximide | Aprepitant | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
1464,
24,
723
]
],
[
[
1464,
6,
6799
],
[
6799,
45,
723
]
],
[
[
1464,
21,
28770
],
[
28770,
60,
723
]
],
[
[
1464,
24,
222
],
[
222,
... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Ethosuximide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compoun... | Ethosuximide (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Aprepitant (Compound)
Ethosuximide (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Aprepitant (Compound)
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine... |
DB00022 | DB09472 | 268 | 1,383 | [
"DDInter1408",
"DDInter1693"
] | Peginterferon alfa-2b | Sodium sulfate | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
268,
24,
1383
]
],
[
[
268,
24,
1613
],
[
1613,
24,
1383
]
],
[
[
268,
63,
491
],
[
491,
24,
1383
]
],
[
[
268,
25,
593
],
[
593,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"P... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Peginterferon alfa-2b may cause a moderate interaction that could exacerbat... |
DB00912 | DB01037 | 473 | 1,161 | [
"DDInter1581",
"DDInter1653"
] | Repaglinide | Selegiline | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Moderate | 1 | [
[
[
473,
24,
1161
]
],
[
[
473,
63,
551
],
[
551,
1,
1161
]
],
[
[
473,
24,
1529
],
[
1529,
1,
1161
]
],
[
[
473,
24,
280
],
[
280,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Selegiline (Co... |
DB00432 | DB01004 | 1,083 | 563 | [
"DDInter1868",
"DDInter806"
] | Trifluridine | Ganciclovir | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
1083,
24,
563
]
],
[
[
1083,
24,
248
],
[
248,
40,
563
]
],
[
[
1083,
6,
10612
],
[
10612,
45,
563
]
],
[
[
1083,
54,
19128
],
[
19128... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],... | Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Trifluridine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Ganciclovir (Compound)
Trifluridine (Compound) is included by Nucleoside ... |
DB00460 | DB01017 | 612 | 1,669 | [
"DDInter1929",
"DDInter1224"
] | Verteporfin | Minocycline | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
612,
24,
1669
]
],
[
[
612,
24,
1572
],
[
1572,
1,
1669
]
],
[
[
612,
63,
964
],
[
964,
1,
1669
]
],
[
[
612,
24,
1545
],
[
1545,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Minocycli... |
DB06228 | DB06636 | 792 | 1,623 | [
"DDInter1609",
"DDInter980"
] | Rivaroxaban | Isavuconazonium | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
792,
24,
1623
]
],
[
[
792,
24,
466
],
[
466,
62,
1623
]
],
[
[
792,
63,
222
],
[
222,
23,
1623
]
],
[
[
792,
63,
1419
],
[
1419,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine ... |
DB00307 | DB00855 | 1,101 | 213 | [
"DDInter203",
"DDInter72"
] | Bexarotene (topical) | Aminolevulinic acid | Bexarotene is a retinoid, a member of benzoic acids and a member of naphthalenes. It has a role as an antineoplastic agent. | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
1101,
25,
213
]
],
[
[
1101,
21,
28880
],
[
28880,
60,
213
]
],
[
[
1101,
23,
1040
],
[
1040,
64,
213
]
],
[
[
1101,
24,
785
],
[
785,... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Angiopathy"
],
[
"Angiopathy",
"{u} (Side Effect) is caused b... | Bexarotene may lead to a major life threatening interaction when taken with Aminolevulinic acid
Bexarotene (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Aminolevulinic acid (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafen... |
DB09030 | DB12825 | 840 | 1,375 | [
"DDInter1945",
"DDInter1032"
] | Vorapaxar | Lefamulin | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
840,
24,
1375
]
],
[
[
840,
24,
159
],
[
159,
63,
1375
]
],
[
[
840,
24,
98
],
[
98,
24,
1375
]
],
[
[
840,
64,
1468
],
[
1468,
... | [
[
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somat... |
DB00749 | DB13074 | 59 | 877 | [
"DDInter699",
"DDInter1110"
] | Etodolac | Macimorelin | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
59,
24,
877
]
],
[
[
59,
24,
1479
],
[
1479,
24,
877
]
],
[
[
59,
63,
251
],
[
251,
24,
877
]
],
[
[
59,
24,
477
],
[
477,
25,
... | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Beta... |
DB00261 | DB00938 | 702 | 455 | [
"DDInter93",
"DDInter1635"
] | Anagrelide | Salmeterol | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
702,
24,
455
]
],
[
[
702,
24,
688
],
[
688,
63,
455
]
],
[
[
702,
25,
371
],
[
371,
63,
455
]
],
[
[
702,
18,
5833
],
[
5833,
4... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Anagrelide may lead to a major life threatening interaction when taken with Propafenone and Propafenone may caus... |
DB00637 | DB09080 | 1,557 | 144 | [
"DDInter128",
"DDInter1331"
] | Astemizole | Olodaterol | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1557,
24,
144
]
],
[
[
1557,
23,
1247
],
[
1247,
23,
144
]
],
[
[
1557,
24,
956
],
[
956,
24,
144
]
],
[
[
1557,
25,
1011
],
[
1011,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin a... |
DB01067 | DB09129 | 959 | 625 | [
"DDInter826",
"DDInter373"
] | Glipizide | Chromic chloride | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Moderate | 1 | [
[
[
959,
24,
625
]
],
[
[
959,
63,
127
],
[
127,
24,
625
]
],
[
[
959,
24,
170
],
[
170,
24,
625
]
],
[
[
959,
24,
1385
],
[
1385,
6... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromic chloride"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Chromic chloride
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitag... |
DB00687 | DB01324 | 870 | 178 | [
"DDInter747",
"DDInter1490"
] | Fludrocortisone | Polythiazide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
870,
24,
178
]
],
[
[
870,
24,
674
],
[
674,
40,
178
]
],
[
[
870,
63,
1014
],
[
1014,
40,
178
]
],
[
[
870,
21,
30696
],
[
30696,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiaz... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) ... |
DB00818 | DB00938 | 898 | 455 | [
"DDInter1538",
"DDInter1635"
] | Propofol | Salmeterol | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
898,
24,
455
]
],
[
[
898,
24,
688
],
[
688,
63,
455
]
],
[
[
898,
6,
8374
],
[
8374,
45,
455
]
],
[
[
898,
21,
29095
],
[
29095,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Propofol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Propofol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Propofol (Compound) ca... |
DB00798 | DB09473 | 1,132 | 884 | [
"DDInter815",
"DDInter918"
] | Gentamicin | Indium In-111 oxyquinoline | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
1132,
24,
884
]
],
[
[
1132,
24,
1448
],
[
1448,
24,
884
]
],
[
[
1132,
63,
50
],
[
50,
24,
884
]
],
[
[
1132,
64,
1441
],
[
1441,
... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomyci... | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00263 | DB00855 | 1,029 | 213 | [
"DDInter1727",
"DDInter72"
] | Sulfisoxazole | Aminolevulinic acid | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
1029,
25,
213
]
],
[
[
1029,
74,
10
],
[
10,
25,
213
]
],
[
[
1029,
1,
1247
],
[
1247,
64,
213
]
],
[
[
1029,
63,
245
],
[
245,
... | [
[
[
"Sulfisoxazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Sulfisoxazole",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken w... | Sulfisoxazole (Compound) resembles Dapsone (Compound) and Sulfisoxazole may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may lead to a major life threatening interaction when taken with Aminolevulinic acid
Sulfisoxazole (Compound) resembles Sulfamethoxazole (Compound) ... |
DB08820 | DB11853 | 1,478 | 230 | [
"DDInter997",
"DDInter1577"
] | Ivacaftor | Relugolix | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
1478,
25,
230
]
],
[
[
1478,
25,
129
],
[
129,
23,
230
]
],
[
[
1478,
24,
1094
],
[
1094,
23,
230
]
],
[
[
1478,
63,
1101
],
[
1101,
... | [
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} ... | Ivacaftor may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause... |
DB01128 | DB01599 | 918 | 1,232 | [
"DDInter204",
"DDInter1523"
] | Bicalutamide | Probucol | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Moderate | 1 | [
[
[
918,
24,
1232
]
],
[
[
918,
62,
112
],
[
112,
23,
1232
]
],
[
[
918,
63,
1555
],
[
1555,
24,
1232
]
],
[
[
918,
24,
927
],
[
927,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probucol"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Probucol
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and O... |
DB00696 | DB00759 | 826 | 1,620 | [
"DDInter665",
"DDInter1783"
] | Ergotamine | Tetracycline | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Moderate | 1 | [
[
[
826,
24,
1620
]
],
[
[
826,
63,
1572
],
[
1572,
40,
1620
]
],
[
[
826,
24,
1669
],
[
1669,
40,
1620
]
],
[
[
826,
6,
8374
],
[
8374,
... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
... | Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) resembles Tetracycli... |
DB14723 | DB15328 | 159 | 829 | [
"DDInter1026",
"DDInter1896"
] | Larotrectinib | Ubrogepant | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
159,
24,
829
]
],
[
[
159,
63,
1476
],
[
1476,
24,
829
]
],
[
[
159,
62,
466
],
[
466,
24,
829
]
],
[
[
159,
64,
1510
],
[
1510,
... | [
[
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and ... |
DB00284 | DB00723 | 1,647 | 1,240 | [
"DDInter11",
"DDInter1176"
] | Acarbose | Methoxamine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system. | Moderate | 1 | [
[
[
1647,
24,
1240
]
],
[
[
1647,
24,
1466
],
[
1466,
24,
1240
]
],
[
[
1647,
24,
455
],
[
455,
63,
1240
]
],
[
[
1647,
63,
73
],
[
73,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxamine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Methoxamine
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Salmet... |
DB00766 | DB09122 | 1,675 | 1,613 | [
"DDInter394",
"DDInter1409"
] | Clavulanic acid | Peginterferon beta-1a | Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1675,
24,
1613
]
],
[
[
1675,
63,
267
],
[
267,
24,
1613
]
],
[
[
1675,
24,
850
],
[
850,
24,
1613
]
],
[
[
1675,
25,
1377
],
[
1377,
... | [
[
[
"Clavulanic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Clavulanic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltre... | Clavulanic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Clavulanic acid may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00427 | DB00683 | 1,233 | 1,382 | [
"DDInter1879",
"DDInter1212"
] | Triprolidine | Midazolam | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
1233,
24,
1382
]
],
[
[
1233,
24,
1216
],
[
1216,
40,
1382
]
],
[
[
1233,
63,
902
],
[
902,
40,
1382
]
],
[
[
1233,
24,
717
],
[
717,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Midazolam (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Midazolam (Compound)
Tr... |
DB00047 | DB01234 | 176 | 1,220 | [
"DDInter932",
"DDInter513"
] | Insulin glargine | Dexamethasone | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
176,
24,
1220
]
],
[
[
176,
24,
870
],
[
870,
1,
1220
]
],
[
[
176,
24,
175
],
[
175,
40,
1220
]
],
[
[
176,
23,
1103
],
[
1103,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortis... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) r... |
DB00843 | DB01611 | 479 | 1,487 | [
"DDInter583",
"DDInter893"
] | Donepezil | Hydroxychloroquine | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
479,
24,
1487
]
],
[
[
479,
23,
1520
],
[
1520,
25,
1487
]
],
[
[
479,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
479,
21,
28658
],
[
2865... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primaquine"
],
... | Donepezil may cause a minor interaction that can limit clinical effects when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Donepezil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Donepezil (Compound) ... |
DB09291 | DB11979 | 741 | 1,320 | [
"DDInter1615",
"DDInter625"
] | Rolapitant | Elagolix | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
741,
24,
1320
]
],
[
[
741,
63,
1427
],
[
1427,
24,
1320
]
],
[
[
741,
64,
129
],
[
129,
24,
1320
]
],
[
[
741,
25,
913
],
[
913,
... | [
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
... | Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Rolapitant may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may ... |
DB00819 | DB01240 | 471 | 885 | [
"DDInter15",
"DDInter657"
] | Acetazolamide | Epoprostenol | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
471,
24,
885
]
],
[
[
471,
63,
1061
],
[
1061,
1,
885
]
],
[
[
471,
21,
28684
],
[
28684,
60,
885
]
],
[
[
471,
24,
1450
],
[
1450,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Acetazolamide (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Epoprostenol (Compound)
Acetazolamide may caus... |
DB06282 | DB14740 | 516 | 771 | [
"DDInter1053",
"DDInter881"
] | Levocetirizine | Hyaluronidase | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permea... | Minor | 0 | [
[
[
516,
23,
771
]
],
[
[
516,
24,
849
],
[
849,
23,
771
]
],
[
[
516,
63,
820
],
[
820,
23,
771
]
],
[
[
516,
24,
849
],
[
849,
24,... | [
[
[
"Levocetirizine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],... | Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine ... |
DB00909 | DB09488 | 306 | 103 | [
"DDInter1971",
"DDInter23"
] | Zonisamide | Acrivastine | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Major | 2 | [
[
[
306,
25,
103
]
],
[
[
306,
64,
85
],
[
85,
24,
103
]
],
[
[
306,
25,
1264
],
[
1264,
24,
103
]
],
[
[
306,
64,
85
],
[
85,
24,
... | [
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acrivastine"
]
],
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may ... | Zonisamide may lead to a major life threatening interaction when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Zonisamide may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction t... |
DB00694 | DB00843 | 51 | 479 | [
"DDInter485",
"DDInter583"
] | Daunorubicin | Donepezil | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Moderate | 1 | [
[
[
51,
24,
479
]
],
[
[
51,
24,
843
],
[
843,
1,
479
]
],
[
[
51,
6,
8374
],
[
8374,
45,
479
]
],
[
[
51,
18,
2900
],
[
2900,
46,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
],
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetrabenazine (Compound) resembles Donepezil (Compound)
Daunorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Donepezil (Compound)
Daunorubicin (Compound) downregulates NFKBIA (Gene) and NF... |
DB06441 | DB11689 | 936 | 321 | [
"DDInter283",
"DDInter1659"
] | Cangrelor | Selumetinib | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
936,
24,
321
]
],
[
[
936,
64,
291
],
[
291,
24,
321
]
],
[
[
936,
25,
498
],
[
498,
24,
321
]
],
[
[
936,
25,
1421
],
[
1421,
6... | [
[
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban"... | Cangrelor may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Cangrelor may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interacti... |
DB00570 | DB11988 | 147 | 270 | [
"DDInter1936",
"DDInter1321"
] | Vinblastine | Ocrelizumab | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
147,
24,
270
]
],
[
[
147,
63,
1461
],
[
1461,
23,
270
]
],
[
[
147,
24,
1060
],
[
1060,
63,
270
]
],
[
[
147,
63,
134
],
[
134,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and... |
DB00238 | DB09030 | 188 | 840 | [
"DDInter1285",
"DDInter1945"
] | Nevirapine | Vorapaxar | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Moderate | 1 | [
[
[
188,
24,
840
]
],
[
[
188,
25,
1017
],
[
1017,
63,
840
]
],
[
[
188,
24,
1496
],
[
1496,
63,
840
]
],
[
[
188,
24,
578
],
[
578,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib"... | Nevirapine may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a... |
DB08899 | DB08934 | 129 | 1,200 | [
"DDInter649",
"DDInter1695"
] | Enzalutamide | Sofosbuvir | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 bein... | Major | 2 | [
[
[
129,
25,
1200
]
],
[
[
129,
6,
4973
],
[
4973,
45,
1200
]
],
[
[
129,
21,
29727
],
[
29727,
60,
1200
]
],
[
[
129,
63,
126
],
[
126,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sofosbuvir"
]
],
[
[
"Enzalutamide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sofos... | Enzalutamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sofosbuvir (Compound)
Enzalutamide (Compound) causes Memory impairment (Side Effect) and Memory impairment (Side Effect) is caused by Sofosbuvir (Compound)
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.